Table 5 Therapeutic response (WHO)

From: Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702

 

CE

SPE

Total

CR

5

5

10

PR

75

75

150

NC

17

11

28

PD

11

16

27

NE

2

3

5

Total

110

110

220

Response rate

73%

73%

 

95% CI

63–81%

63–81%

 
  1. CE, carboplatin plus etoposide; CI, confidence interval; CR, complete response; NC, no change; NE, not evaluable; PD, progressive disease; PR, partial response; SPE, split doses of cisplatin plus etoposide; WHO, World Health Organization.
Back to article page